BOSTON – (September 17, 2013) – The First Helmholtz Diabetes Lecture Award will be presented to C. Ronald Kahn, M.D. at the upcoming Helmholtz-Nature Medicine Diabetes Conference. Dr Kahn is a resident of Newton, MA, and Chief Academic Officer of Joslin Diabetes Center. He will receive this honor at the conference on September 22 - 24, 2013 in Munich, Germany.

The Helmholtz Diabetes Award recognizes the lifetime achievements of a senior leader in the field of diabetes research.  

“I was surprised and pleased that my work is recognized by this new lifetime achievement award, and having this award occur at a great meeting and in connection with Nature Medicine makes the award even more prestigious,” said Dr. Kahn.

“We couldn’t be more excited that Dr. Kahn is accepting this award,” said Dr. Matthias Tschöp, Director of the Helmholtz Diabetes Center in Munich and co-organizer of the conference.  “Dr. Kahn repeatedly has transformed the way we think about insulin action and metabolic control.” 

This conference will bring together the top leaders in the field of diabetes to organize the identification of, and potential solutions to, the challenges facing the prevention and treatment of type 2 diabetes. 

In addition to his role as Chief Academic Officer at Joslin, Dr. Kahn is head of Joslin’s Integrative Physiology and Metabolism section and the Mary K. Iacocca Professor of Medicine at Harvard Medical School, where he has been a member of the faculty since 1981 when he joined Joslin as Research Director for two decades. He then served as Joslin’s President from 2000 - 2007. Under his leadership, Joslin’s research grew more than 20-fold, and clinical and educational activity tripled.

Dr. Kahn is also a renowned investigator of insulin signal transduction and the mechanisms of altered signaling in disease. His laboratory discovered the insulin receptor kinase, its two primary substrates and the molecular components of the insulin-signaling network. He was the first to define alterations in the signaling network in type 2 diabetes, including the important role of insulin action in unexpected tissues such as brain, both in physiologic regulation and potentially in development of Alzheimer’s Disease.

###

Related Articles

A Scientist working in lab
Type 1
Kidney Disease
Research Highlights

The Preventing Early Renal Loss in Diabetes (PERL) Study Conclusion

The Preventing Early Renal Loss in Diabetes (PERL) Study Conclusion

Three-year clinical trial finds reducing uric acid levels in type 1 diabetes provides no beneficial impact on the progression of diabetic kidney disease BOSTON – (November 8, 2019) – Diabetic kidney...
Read more on The Preventing Early Renal Loss in Diabetes (PERL) Study Conclusion
National Diabetes Month
Type 1
Type 2

National Diabetes Awareness Month

National Diabetes Awareness Month

Diabetes is growing at an epidemic rate in the United States and across the globe. According to the Centers for Disease Control and Prevention (CDC), over 30 million Americans have diabetes and 1.5...
Read more on National Diabetes Awareness Month
Red blood cell traveling in an artery
Type 1
Heart Disease
Research Highlights

Research may show way to minimize complications after heart treatment

Research may show way to minimize complications after heart treatment

BOSTON – (October 1, 2019) – People with diabetes are much more likely to develop heart disease than those without the condition. They also are several times more likely to develop complications after...
Read more on Research may show way to minimize complications after heart treatment